Zawistowski, Jon S <br/><br/>
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.  [electronic resource] 

 -  Cancer discovery  03 2017 
 - 302-321 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>2159-8290 
<br/><br/><label>Standard No.: </label>10.1158/2159-8290.CD-16-0653  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Azepines--pharmacology<br/>Cell Cycle Proteins<br/>Cell Line, Tumor<br/>DNA Methylation<br/>Discoidin Domain Receptor 1--genetics<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>Enhancer Elements, Genetic<br/>Epigenesis, Genetic<br/>Female<br/>Heterocyclic Compounds, 4 or More Rings--pharmacology<br/>Humans<br/>MAP Kinase Kinase 1--antagonists & inhibitors<br/>MAP Kinase Kinase 2--antagonists & inhibitors<br/>Mice, Inbred BALB C<br/>Mice, SCID<br/>Molecular Targeted Therapy<br/>Nuclear Proteins--antagonists & inhibitors<br/>Positive Transcriptional Elongation Factor B--antagonists & inhibitors<br/>Pyridones--pharmacology<br/>Pyrimidinones--pharmacology<br/>RNA Interference<br/>Transcription Factors--antagonists & inhibitors<br/>Triazoles--pharmacology<br/>Triple Negative Breast Neoplasms--drug therapy<br/>Xenograft Model Antitumor Assays